BIO-TECHNE Corp (NASDAQ:TECH) Shares Acquired by Stifel Financial Corp

Share on StockTwits

Stifel Financial Corp lifted its stake in shares of BIO-TECHNE Corp (NASDAQ:TECH) by 11.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,315 shares of the biotechnology company’s stock after purchasing an additional 969 shares during the quarter. Stifel Financial Corp’s holdings in BIO-TECHNE were worth $1,825,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Voya Investment Management LLC grew its stake in BIO-TECHNE by 12.7% in the 3rd quarter. Voya Investment Management LLC now owns 15,368 shares of the biotechnology company’s stock valued at $3,007,000 after acquiring an additional 1,729 shares during the last quarter. First Allied Advisory Services Inc. acquired a new stake in BIO-TECHNE in the 3rd quarter valued at about $210,000. Northwestern Mutual Investment Management Company LLC grew its stake in BIO-TECHNE by 0.5% in the 3rd quarter. Northwestern Mutual Investment Management Company LLC now owns 10,853 shares of the biotechnology company’s stock valued at $2,124,000 after acquiring an additional 52 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in BIO-TECHNE by 3.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 951,301 shares of the biotechnology company’s stock valued at $186,141,000 after acquiring an additional 31,700 shares during the last quarter. Finally, Eagle Asset Management Inc. grew its stake in BIO-TECHNE by 1.8% in the 3rd quarter. Eagle Asset Management Inc. now owns 48,486 shares of the biotechnology company’s stock valued at $9,487,000 after acquiring an additional 871 shares during the last quarter. 93.11% of the stock is currently owned by institutional investors and hedge funds.

In other BIO-TECHNE news, CEO Charles R. Kummeth sold 11,772 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $222.12, for a total transaction of $2,614,796.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Roeland Nusse sold 8,347 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $219.33, for a total transaction of $1,830,747.51. Following the sale, the director now directly owns 15,721 shares in the company, valued at $3,448,086.93. The disclosure for this sale can be found here. Insiders have sold a total of 34,271 shares of company stock worth $7,503,700 over the last ninety days. 4.20% of the stock is owned by corporate insiders.

A number of equities research analysts recently commented on the stock. TheStreet raised shares of BIO-TECHNE from a “c+” rating to a “b-” rating in a research note on Wednesday, November 27th. Leerink Swann reissued an “outperform” rating and issued a $240.00 price objective (up from $230.00) on shares of BIO-TECHNE in a research note on Thursday, September 26th. Stifel Nicolaus assumed coverage on shares of BIO-TECHNE in a research note on Thursday, November 14th. They issued a “buy” rating and a $235.00 price objective on the stock. ValuEngine cut shares of BIO-TECHNE from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. Finally, BidaskClub raised shares of BIO-TECHNE from a “sell” rating to a “hold” rating in a research note on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. BIO-TECHNE has a consensus rating of “Hold” and a consensus price target of $224.50.

BIO-TECHNE stock opened at $218.31 on Friday. BIO-TECHNE Corp has a 12-month low of $132.75 and a 12-month high of $222.87. The stock has a market capitalization of $8.36 billion, a P/E ratio of 57.45, a P/E/G ratio of 4.69 and a beta of 1.23. The firm’s 50-day moving average is $212.12 and its two-hundred day moving average is $204.45. The company has a debt-to-equity ratio of 0.47, a current ratio of 4.44 and a quick ratio of 3.41.

BIO-TECHNE (NASDAQ:TECH) last released its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $1.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.14. BIO-TECHNE had a net margin of 12.68% and a return on equity of 13.36%. The company had revenue of $183.24 million for the quarter, compared to analysts’ expectations of $179.38 million. During the same period last year, the company earned $0.98 EPS. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. As a group, analysts forecast that BIO-TECHNE Corp will post 4.25 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, November 22nd. Shareholders of record on Friday, November 8th were paid a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, November 7th. This represents a $1.28 annualized dividend and a dividend yield of 0.59%. BIO-TECHNE’s dividend payout ratio is currently 33.68%.

BIO-TECHNE Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

Further Reading: What is the Gross Domestic Product (GDP)?

Institutional Ownership by Quarter for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Abbott Laboratories  Updates FY 2020
Pre-Market Earnings Guidance
Abbott Laboratories Updates FY 2020 Pre-Market Earnings Guidance
Express  Releases Q4 2019
Pre-Market Earnings Guidance
Express Releases Q4 2019 Pre-Market Earnings Guidance
MarineMax  Updates FY20 Earnings Guidance
MarineMax Updates FY20 Earnings Guidance
Squar Milner Financial Services LLC Cuts Position in Invesco BulletShares 2022 Corporate Bond ETF
Squar Milner Financial Services LLC Cuts Position in Invesco BulletShares 2022 Corporate Bond ETF
Vanguard Russell 2000  Stock Position Trimmed by Janney Montgomery Scott LLC
Vanguard Russell 2000 Stock Position Trimmed by Janney Montgomery Scott LLC
Janney Montgomery Scott LLC Has $14.72 Million Stake in L3Harris
Janney Montgomery Scott LLC Has $14.72 Million Stake in L3Harris


 
© 2006-2020 Zolmax.